Latest Antihelminthics Companies Update
Jan 2024
Johnson & Johnson Collaborating with WHO and other partners on the "Transform 80/20" initiative aiming to treat 80% of school-aged children with STHs by 2025.Investing in research and development of new long-acting antihelminthics for improved efficacy and reduced treatment frequency in mass drug administration programs.
Merck & Co. Received FDA approval for their new once-daily antihelminthic medication, MECTIZAN® (ivermectin), for treating onchocerciasis (river blindness).Partnering with non-profit organizations to expand access to MECTIZAN® in affected communities and contribute to onchocerciasis elimination efforts.
Eisai Co. Announced the availability of their broad-spectrum anthelminthic, praziquantel, in a chewable tablet formulation, aiming for improved medication adherence among children and addressing swallowing difficulties.Joined the WHO initiative "Global Platform for Accelerating Elimination of Soil-Transmitted Helminthiasis" to contribute to research and development efforts.
GlaxoSmithKline (GSK) Launched a new educational campaign raising awareness about helminthic infections and the importance of preventive measures like sanitation and hygiene practices.Collaborated with local governments and healthcare providers to strengthen infrastructure and healthcare systems in high-burden areas for effective worm control strategies.
List of Antihelminthics Key Companies in the Market
- Abbott
- Novartis AG
- ZEISS International
- Johnson & Johnson Services, Inc.
- Sanofi
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Astellas Pharma Inc.
- Bayer AG
- Mentis Pharma Ltd.
- Pfizer Inc.
- Sanofi
- ALLERGAN
- AstraZeneca